Definition of liver tumors in the presence of diffuse liver disease: Comparison of findings at MR imaging with positive and negative contrast agents

Radiology

Volumn 202, Issue 1, 1997, Pages 131-138

  Kuwatsuru, Ryohei ^a,c   Brasch, Robert C ^a   Mühler, Andreas ^a   Mathur, Ashwini ^a   Vexler, Vladimir S ^a   Rosenau, Werner ^b   Mintorovitch, Jan ^a   Berthezene, Yves ^a   Cohen, Frederic ^a   Shames, David M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JUNTENDO UNIVERSITY   (Japan)

Author keywords

Contrast media, experimental studies; Gadolinium; Iron; Liver neoplasms, MR; Liver, diseases; Magnetic resonance (MR), contrast enhancement

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE DERIVATIVE; GADOLINIUM PENTETATE MEGLUMINE; GADOXETIC ACID; SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ACUTE HEPATITIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER DIAGNOSIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FATTY LIVER; FEMALE; HISTOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LIVER CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TUMOR; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SIGNAL NOISE RATIO;

EID: 0031030752     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.202.1.8988202     Document Type: Article

References (44)

1. Reinig J, Dwyer A, Miller D, et al. Liver metastasis detection: comparative sensitivities of MR imaging and CT scanning. Radiology 1987; 162:43-47.
2. Stark D, Wittenberg J, Edelman R, et al. Detection of hepatic metastases: analysis of pulse sequence performance in MR imaging. Radiology 1986; 159:365-370.
3. Stark D, Wittenberg J, Butch R, Ferrucci J Jr. Hepatic metastases: randomized, controlled comparison of detection with MR imaging and CT. Radiology 1987; 165:399-406.
4. Heiken J, Weyman P, Lee J, et al. Detection of focal hepatic masses: prospective evaluation with CT, delayed CT, CT during arterial portography, and MR imaging. Radiology 1989; 171:47-51.
5. Nelson R, Chezmar J, Sugarbaker P, Bernardino M. Hepatic tumors: comparison of CT during arterial portography, delayed CT, and MR imaging for preoperative evaluation. Radiology 1989; 172:27-34.
6. Ward B, Miller D, Frank J, et al. Prospective evaluation of hepatic imaging studies in the detection of colorectal metastases: correlation with surgical findings. Surgery 1989; 105:180-187.
7. Mano I, Yoshida H, Nakabayashi K, Yashiro N, Iio M. Fast spin echo imaging with suspended respiration: gadolinium enhanced MR imaging of liver tumors. J Comput Assist Tomogr 1987; 11:73-80.
8. Hamm B, Wolf K, Felix R. Conventional and rapid MR imaging of the liver with Gd-DTPA. Radiology 1987; 164:313-320.
9. Schmiedl U, Köbel G, Hess C, Klose U, Kurtz B. Dynamic sequential MR imaging of focal liver lesions: initial experience in 22 patients at 1.5 T. J Comput Assist Tomogr 1990; 14:600-607.
10. Carr D, Graif M, Niendorf H, et al. Gadolinium-DTPA in the assessment of liver tumours by magnetic resonance imaging. Clin Radiol 1986; 37:347-353.
11. Edelman R, Siegel J, Singer A, Dupuis K, Longmaid H. Dynamic MR imaging of the liver with Gd-DTPA: initial clinical results. AJR 1989; 153:1213-1219.
12. Mirowitz S, Lee J, Gutierrez E, Brown J, Heiken J, Eilenberg S. Dynamic gadolinium-enhanced rapid acquisition spin-echo MR imaging of the liver. Radiology 1991; 179:371-376.
13. Weinmann H, Schuhmann-Giampieri G, Schmitt-Willich H, Vogler H, Frenzel T, Cries H. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 1991; 22:233-237.
14. Schuhmann-Giampieri G, Schmitt-Willich H, Press W, Negishi C, Weinmann H, Speck U. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 1992; 183:59-64.
15. Mühler A, Clément O, Vexler V, Berthezène Y, Rosenau W, Brasch R. Hepatobiliary enhancement with Gd-EOB-DTPA: comparison of spin-echo and STIR imaging for detection of experimental liver metastases. Radiology 1992; 184:207-213.
16. Clément O, Mühler A, Vexler V, Berthezène Y, Brasch R. Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Invest Radiol 1992; 27:612-619.
17. Clément O, Muhler A, Vexler V, et al. Comparison of Gd-EOB-DTPA and Gd-DTPA for contrast-enhanced MR imaging of liver tumors. JMRI 1993; 3:71-77.
18. Saini S, Stark D, Hahn P, Wittenberg J, Brady T, Ferrucci JJ. Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system. Radiology 1987; 162:211-216.
19. Weissleder R, Stark D, Engelstad B, et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR 1989; 152:167-173.
20. Hecke P, Marchai G, Decrop E, Baert A. Experimental study of the pharmacokinetics and dose response of ferrite particles used as a contrast agent in MRI of the normal liver of the rabbit. Invest Radiol 1988; 24:397-399.
21. Farber E, Simpson M, Tarver H. Studies on ethionine. II. The interference with lipid metabolism. J Biol Chem 1950; 182:91-99.
22. Recknagel R. Carbon tetrachloride hepatotoxicity. Pharmacol Rev 1967; 19:145-208.
23. Proctor E, Chatamra K. Controlled induction of cirrhosis in the rat. Br J Exp Pathol 1983; 64:320-330.
24. Proctor E, Chatamra K. Standardized micronodular cirrhosis in the rat. Eur J Res 1984; 16:182-186.
25. Fleiss J. The design and analysis of clinical experiments. New York, NY: Wiley, 1986; 46-90.
26. Reimer P, Weissleder R, Lee A, Buettner S, Wittenberg J, Brady T. Asialoglycoprotein receptor function in benign liver disease: evaluation with MR imaging. Radiology 1991; 178:769-774.
27. Majumdar S, Zoghbi S, Gore J. Pharmacokinetics of superparamagnetic iron-oxide MR contrast agents in the rat. Invest Radiol 1990; 25:771-777.
28. Saini S, Stark D, Hahn P, et al. Ferrite particles: a superparamagnetic MR contrast agent for enhanced detection of liver carcinoma. Radiology 1987; 162:217-222.
29. Weissleder R, Stark D, Compton C, Wittenberg J, Ferrucci J. Ferrite-enhanced MR imaging of hepatic lymphoma: an experimental study in rats. AJR 1987; 149:1161-1165.
30. Tsang T, Stark D, Chen M, Weissleder R, Wittenberg J, Ferrucci J. Hepatic micrometastases in the rat: ferrite-enhanced MR imaging. Radiology 1988; 167:21-24.
31. Stark D, Weissleder R, Elizondo G, et al. Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology 1988; 168:297-301.
32. Clément O, Frija G, Chambon C, et al. Liver tumors in cirrhosis: experimental study with SPIO-enhanced MR imaging. Radiology 1991; 180:31-36.
33. Wenker J, Baker M, Ellis J, Giant M. Focal fatty infiltration of the liver: demonstration by magnetic resonance imaging. AJR 1984; 143:573-574.
34. Stark D, Bass N, Moss A, et al. Nuclear magnetic resonance imaging of experimentally induced liver disease. Radiology 1983; 148:743-751.
35. 4 hepatotoxicity. Magn Reson Med 1991; 19:124-135.
36. 1H magnetic resonance, total lipid analysis, and histology. Magn Reson Med 1990; 15: 211-228.
37. Towner R, Reinke L, Janzen E, Yamashiro S. Enhancement of carbon tetrachloride-induced liver injury by a single dose of ethanol: proton magnetic resonance imaging (MRI) studies in vivo. Biochim Biophys Acta 1991; 1096:222-230.
38. Brauer M, Towner R, Renaud I, Janzen E, Foxall D. In vivo proton nuclear magnetic resonance imaging and spectroscopy studies of halocarbon-induced liver damage. Magn Reson Med 1989; 9:229-239.
39. Young I, Bailes D, Burl M, et al. Initial clinical evaluation of a whole body nuclear magnetic resonance (NMR) tomograph. J Comput Assist Tomogr 1982; 6:1-18.
40. Smith F, Mallard J, Reid A, Hutchison J. Nuclear magnetic resonance tomographic imaging in liver disease. Lancet 1981; 1:963-966.
41. Thomsen C, Christoffersen P, Henriksen O, Juhl E. Prolonged T1 in patients with liver cirrhosis: an in vivo MRI study. Magn Reson Imaging 1990; 8:599-604.
42. Ebara M, Ohto M, Watanabe Y, et al. Diagnosis of small hepatocellular carcinoma: correlation of MR imaging and tumor histologic studies. Radiology 1986; 159:371-377.
43. Chamuleau R, Creyghton J, De Nie I, Moerland M, Van Der Lende O, Smidt J. Is the magnetic resonance imaging proton spin-lattice relaxation time a reliable noninvasive parameter of developing liver fibrosis? Hepatology 1988; 8:217-221.
44. Hamm B, Staks T, Mühler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195:785-792.